Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-week...

Full description

Bibliographic Details
Main Authors: Celeste M. Boesjes, Esmé Kamphuis, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Laura Loman, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Anneke M.T. van Lynden-van Nes, Floor M. Garritsen, Klaziena Politiek, Marja Oldhoff, Marlies de Graaf, Marie L.A. Schuttelaar, Marjolein S. de Bruin-Weller
Format: Article
Language:English
Published: Medical Journals Sweden 2022-11-01
Series:Acta Dermato-Venereologica
Subjects:
atopic dermatitis
baricitinib
daily practice
JAK-inhibitor
PROMs
Online Access:https://medicaljournalssweden.se/actadv/article/view/3978

Internet

https://medicaljournalssweden.se/actadv/article/view/3978

Similar Items